Literature DB >> 7584958

The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis.

D J Grainger1, P R Kemp, J C Metcalfe, A C Liu, R M Lawn, N R Williams, A A Grace, P M Schofield, A Chauhan.   

Abstract

Recent evidence has led us to propose that transforming growth factor-beta (TGF-beta) is a key inhibitor of atherosclerosis. We show here that a population of patients with advanced atherosclerosis all have less active TGF-beta in their sera than patients with normal coronary arteries, with a fivefold difference in average concentration between the two groups. This correlation with atherosclerosis is much stronger than for other known major risk factors and it may therefore have important diagnostic and prognostic significance. Aspirin medication correlates with an increase in active TGF-beta concentration, indicating that therapeutic interventions for TGF-beta are possible.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7584958     DOI： 10.1038/nm0195-74

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  70 in total

Review 1.  Latent-TGF-beta: an overview.

Authors:  D A Lawrence
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study.

Authors:  Isha Agarwal; Alice Arnold; Nicole L Glazer; Eddy Barasch; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Richard A Jensen; Jorge R Kizer; Eric B Rimm; David S Siscovick; Russell P Tracy; Tien Y Wong; Kenneth J Mukamal
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

3.  A mechanism by which dietary trans fats cause atherosclerosis.

Authors:  Chun-Lin Chen; Laura H Tetri; Brent A Neuschwander-Tetri; Shuan Shian Huang; Jung San Huang
Journal:  J Nutr Biochem       Date:  2010-10-30       Impact factor: 6.048

Review 4.  Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.

Authors:  Ian Toma; Timothy A McCaffrey
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 5.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

6.  Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis.

Authors:  Chun-Lin Chen; I-Hua Liu; Steven J Fliesler; Xianlin Han; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Sci       Date:  2007-09-18       Impact factor: 5.285

7.  Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression.

Authors:  Oana Herlea-Pana; Longbiao Yao; Janet Heuser-Baker; Qiongxin Wang; Qilong Wang; Constantin Georgescu; Ming-Hui Zou; Jana Barlic-Dicen
Journal:  Cardiovasc Res       Date:  2015-03-12       Impact factor: 10.787

8.  The association between transforming growth factor-beta gene promoter C-509T polymorphism and Chinese children with Henoch-Schönlein purpura.

Authors:  Yao-Hsu Yang; Huey-Jen Lai; Cheng-Kai Kao; Yu-Tsan Lin; Bor-Luen Chiang
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

9.  Kruppel-like factor KLF10 targets transforming growth factor-beta1 to regulate CD4(+)CD25(-) T cells and T regulatory cells.

Authors:  Zhuoxiao Cao; Akm Khyrul Wara; Basak Icli; Xinghui Sun; René R S Packard; Fehim Esen; Christopher J Stapleton; Malayannan Subramaniam; Karsten Kretschmer; Irina Apostolou; Harald von Boehmer; Göran K Hansson; Thomas C Spelsberg; Peter Libby; Mark W Feinberg
Journal:  J Biol Chem       Date:  2009-07-14       Impact factor: 5.157

10.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.